πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

Showing page 51 of 857 Β· Phase 3 first, then by program name

  1. Dabrafenib

    Novartis Pharmaceuticals

    Malignant Melanoma

    phase 3 small molecule completed

    1 trial

  2. Daclatasvir

    Bristol-Myers Squibb

    Hepatitis C Virus Infection

    phase 3 small molecule completed

    2 trials

  3. Dactinomycin

    Children's Hospital of Fudan University

    Adult Kidney Wilms Tumor

    phase 3 mab active

    1 trial

  4. Danicopan

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  5. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction (HFpEF)

    phase 3 small molecule completed

    1 trial

  6. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  7. Dapagliflozin

    AstraZeneca

    Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

    phase 3 small molecule completed

    1 trial

  8. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction

    phase 3 small molecule completed

    1 trial

  9. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    3 trials

  10. Dapagliflozin 10 mg

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

    phase 3 small molecule completed

    1 trial

  11. Dapagliflozin 10 mg

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  12. Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pediatric Hereditary Kidney Diseases

    phase 3 small molecule active

    1 trial

  13. Dara SC

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  14. Daratumumab

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    3 trials

  15. Daratumumab, DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE

    Celltrion Healthcare Australia Pty Ltd

    Refractory or Relapsed Multiple Myeloma

    phase 3 small molecule active

    1 trial

  16. Darbepoetin alfa

    Amgen

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  17. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  18. Darovasertib

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    2 trials

  19. Darvadstrocel

    Takeda

    Complex Perianal Fistulas in Adult Participants With Crohn's Disease

    phase 3 mab completed

    1 trial

  20. Dasiglucagon 4 mg/ml

    Zealand Pharma A/S

    Children with congenital hyperinsulinism

    phase 3 small molecule active

    1 trial

  21. Dato-DXd

    AstraZeneca

    Breast Cancer

    phase 3 small molecule active

    2 trials

  22. Datopotamab deruxtecan, DOCETAXEL

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  23. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  24. Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources